Sucampo Announces Webcast of Its Presentation at Piper Jaffray 27th Annual Healthcare Conference
November 25 2015 - 6:30AM
Sucampo Pharmaceuticals, Inc. (Nasdaq:SCMP), a global
biopharmaceutical company, today announced that it will webcast its
corporate presentation at Piper Jaffray 27th Annual Healthcare
Conference on Wednesday, December 2, 2015 at 11:10AM ET.
Investors interested in arranging a meeting with the Company's
management during this conference should contact the conference
coordinator.
The presentation will be webcast live and may be accessed from
the Events & Presentations page of Sucampo's website at
http://www.sucampo.com/investors/events-presentations/.
Presentation slides will be available via the webcast links. A
replay of the webcast will also be available on the Company's
website for several days after the live event. To ensure a timely
connection, it is recommended that users register at least 15
minutes prior to the scheduled webcast.
About Sucampo Pharmaceuticals, Inc.
Sucampo Pharmaceuticals, Inc., is focused on the development and
commercialization of medicines that meet major unmet medical needs
of patients worldwide. Sucampo has one marketed product - AMITIZA -
and a pipeline of product candidates in clinical
development. A global company, Sucampo is headquartered in
Rockville, Maryland, and has operations in Japan, Switzerland and
the U.K. For more information, please visit www.sucampo.com.
The Sucampo logo and the tagline, The Science of Innovation, are
registered trademarks of Sucampo AG. AMITIZA is a registered
trademark of Sucampo AG.
Follow us on Twitter (@Sucampo_Pharma). Follow us on LinkedIn
(Sucampo Pharmaceuticals).
Twitter LinkedIn
Sucampo Forward-Looking Statement
This press release contains "forward-looking statements" as that
term is defined in the Private Securities Litigation Reform Act of
1995. These statements are based on management's current
expectations and involve risks and uncertainties, which may cause
results to differ materially from those set forth in the
statements. The forward-looking statements may include statements
regarding financial results for the full years ending December 31,
2015 and 2016, as well as statements about potential future revenue
growth, statements regarding the acquisition of R-Tech Ueno and the
integration of its business and operations with that of Sucampo,
and statements regarding product development, and other statements
that are not historical facts. The following factors, among others,
could cause actual results to differ from those set forth in the
forward-looking statements: the impact of pharmaceutical industry
regulation and health care legislation; the ability of Sucampo to
continue to develop the market for AMITIZA; the ability of Sucampo
to develop, commercialize or license existing pipeline products or
compounds or license or acquire non-prostone products or drug
candidates; Sucampo's ability to accurately predict future market
conditions; dependence on the effectiveness of Sucampo's patents
and other protections for innovative products; the risk of new and
changing regulation and health policies in the U.S. and
internationally; the effects of competitive products on Sucampo's
products; risks relating to Sucampo's financing for the R-Tech Ueno
acquisition, including the restrictive covenants undertaken by
Sucampo as part of the financing; risks related to the squeeze-out
of R-Tech Ueno minority stockholders under Japanese law; Sucampo's
ability to successfully integrate R-Tech Ueno's operations
following the close of the acquisition; and the exposure to
litigation and/or regulatory actions.
No forward-looking statement can be guaranteed and actual
results may differ materially from those projected. Sucampo
undertakes no obligation to publicly update any forward-looking
statement, whether as a result of new information, future events,
or otherwise. Forward-looking statements in this press release
should be evaluated together with the many uncertainties that
affect Sucampo's business, particularly those mentioned in the risk
factors and cautionary statements in Sucampo's most recent Form
10-K as filed with the Securities and Exchange Commission on March
9, 2015 as well as its filings with the Securities and Exchange
Commission on Forms 8-K and 10-Q since the filing of the Form 10-K,
all of which Sucampo incorporates by reference.
CONTACT: Sucampo Pharmaceuticals, Inc.
Silvia Taylor
Senior Vice President, Investor Relations and Corporate Affairs
1-240-223-3718
staylor@sucampo.com
Sucampo Pharmaceuticals, Inc. (delisted) (NASDAQ:SCMP)
Historical Stock Chart
From Mar 2024 to Apr 2024
Sucampo Pharmaceuticals, Inc. (delisted) (NASDAQ:SCMP)
Historical Stock Chart
From Apr 2023 to Apr 2024